NCT01941758View on ClinicalTrials.gov

High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Central Nervous System Neoplasm
Interventions
BIOLOGICAL

trivalent influenza vaccine

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (2)

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore

27157

Comprehensive Cancer Center of Wake Forest University, Winston-Salem

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT01941758 - High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors | Biotech Hunter | Biotech Hunter